https://www.selleckchem.com/products/cpi-0610.html
f patients with advanced STS, treatment with doxorubicin plus olaratumab vs doxorubicin plus placebo resulted in no significant difference in overall survival. The findings did not confirm the overall survival benefit observed in the phase 2 trial. Trial Registration ClinicalTrials.gov Identifier NCT02451943.AIMS Calcific aortic valve disease is the most common heart valve disease in the Western world. It has been reported that zinc is accumulated in calcified human aortic valves. However, whether zinc directly regulates calcific aorti